{"id":458400,"date":"2021-03-16T07:31:32","date_gmt":"2021-03-16T11:31:32","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=458400"},"modified":"2021-03-16T07:31:32","modified_gmt":"2021-03-16T11:31:32","slug":"tearclear-moving-toward-clinical-trials-and-strengthening-leadership-team","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-moving-toward-clinical-trials-and-strengthening-leadership-team\/","title":{"rendered":"TearClear Moving Toward Clinical Trials and Strengthening Leadership Team"},"content":{"rendered":"
\n

BOSTON, March 16, 2021 (GLOBE NEWSWIRE) — TearClear continues to make progress on the development of its first-in-class platform of preservative-free topical medications. With a successful Pre-IND meeting with the US FDA achieved in Nov. 2020, the TearClear team is now advancing the preparation of clinical trial material required for its proprietary latanoprost pivotal study in anticipation of an IND submission later this year.\u00a0 Today, TearClear also announces the appointment of Stuart Raetzman to interim CEO. Stuart is a TearClear Board Member and long-term Industry veteran with a proven track record of building successful pharmaceutical businesses. Raetzman commented, \u201cTearClear thanks Robert Dempsey for his contributions and wishes him well. We are excited for the Company\u2019s next chapter as we scale our platform and advance our innovative ophthalmic pharmaceutical portfolio. At TearClear, our goal is to disrupt the way current topical medications are delivered to the ocular surface.\u201d<\/p>\n

\n About TearClear
<\/strong>TearClear is an emerging ophthalmic pharmaceutical company with the goal of disrupting the way current topical medications are delivered to the ocular surface.\u00a0Our lead product candidates in glaucoma will pave the way for future indications across multiple\u00a0programs in development. This novel\u00a0platform of drugs enables medication delivery to ultimately enhance patient safety and compliance by capturing preservatives before they reach the ocular surface.\u00a0TearClear is based in Boston, MA. For more information, visit\u00a0TearClear<\/a> and connect with us on LinkedIn: LinkedIn<\/a>.<\/p>\n

\n About Preservative Free
<\/strong>Preservatives, such as\u00a0benzalkonium chloride\u00a0(BAK), are necessary in ophthalmic solutions to maintain sterility.\u00a0However, on the ocular surface, they have been reported to be associated with\u00a0adverse effects like\u00a0hyperemia, tear film instability and conjunctival inflammation potentially leading to meibomian gland dysfunction (MGD). By removing preservatives from the ocular surface, the potential for long term\u00a0deleterious effects on the eye are reduced.\u00a0TearClear offers the only means of delivering a preservative-free dose directly from preserved solutions.<\/p>\n

Contact:
Patrick Crowley
TearClear
859-462-4245
pcrowley@strategicadvisersllc.com<\/a><\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

BOSTON, March 16, 2021 (GLOBE NEWSWIRE) — TearClear continues to make progress on the development of its first-in-class platform of preservative-free topical medications. With a successful Pre-IND meeting with the US FDA achieved in Nov. 2020, the TearClear team is now advancing the preparation of clinical trial material required for its proprietary latanoprost pivotal study in anticipation of an IND submission later this year.\u00a0 Today, TearClear also announces the appointment of Stuart Raetzman to interim CEO. Stuart is a TearClear Board Member and long-term Industry veteran with a proven track record of building successful pharmaceutical businesses. Raetzman commented, \u201cTearClear thanks Robert Dempsey for his contributions and wishes him well. We are excited for the Company\u2019s next chapter as we scale … <\/p>\n

Continue reading “TearClear Moving Toward Clinical Trials and Strengthening Leadership Team”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-458400","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nTearClear Moving Toward Clinical Trials and Strengthening Leadership Team - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-moving-toward-clinical-trials-and-strengthening-leadership-team\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TearClear Moving Toward Clinical Trials and Strengthening Leadership Team - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, March 16, 2021 (GLOBE NEWSWIRE) — TearClear continues to make progress on the development of its first-in-class platform of preservative-free topical medications. With a successful Pre-IND meeting with the US FDA achieved in Nov. 2020, the TearClear team is now advancing the preparation of clinical trial material required for its proprietary latanoprost pivotal study in anticipation of an IND submission later this year.\u00a0 Today, TearClear also announces the appointment of Stuart Raetzman to interim CEO. Stuart is a TearClear Board Member and long-term Industry veteran with a proven track record of building successful pharmaceutical businesses. Raetzman commented, \u201cTearClear thanks Robert Dempsey for his contributions and wishes him well. We are excited for the Company\u2019s next chapter as we scale … Continue reading "TearClear Moving Toward Clinical Trials and Strengthening Leadership Team"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-moving-toward-clinical-trials-and-strengthening-leadership-team\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-16T11:31:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDg4MCM0MDY0ODUxIzIwODc3MjU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tearclear-moving-toward-clinical-trials-and-strengthening-leadership-team\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tearclear-moving-toward-clinical-trials-and-strengthening-leadership-team\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"TearClear Moving Toward Clinical Trials and Strengthening Leadership Team\",\"datePublished\":\"2021-03-16T11:31:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tearclear-moving-toward-clinical-trials-and-strengthening-leadership-team\\\/\"},\"wordCount\":327,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tearclear-moving-toward-clinical-trials-and-strengthening-leadership-team\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDg4MCM0MDY0ODUxIzIwODc3MjU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tearclear-moving-toward-clinical-trials-and-strengthening-leadership-team\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tearclear-moving-toward-clinical-trials-and-strengthening-leadership-team\\\/\",\"name\":\"TearClear Moving Toward Clinical Trials and Strengthening Leadership Team - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tearclear-moving-toward-clinical-trials-and-strengthening-leadership-team\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tearclear-moving-toward-clinical-trials-and-strengthening-leadership-team\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDg4MCM0MDY0ODUxIzIwODc3MjU=\",\"datePublished\":\"2021-03-16T11:31:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tearclear-moving-toward-clinical-trials-and-strengthening-leadership-team\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tearclear-moving-toward-clinical-trials-and-strengthening-leadership-team\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tearclear-moving-toward-clinical-trials-and-strengthening-leadership-team\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDg4MCM0MDY0ODUxIzIwODc3MjU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDg4MCM0MDY0ODUxIzIwODc3MjU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tearclear-moving-toward-clinical-trials-and-strengthening-leadership-team\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TearClear Moving Toward Clinical Trials and Strengthening Leadership Team\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TearClear Moving Toward Clinical Trials and Strengthening Leadership Team - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-moving-toward-clinical-trials-and-strengthening-leadership-team\/","og_locale":"en_US","og_type":"article","og_title":"TearClear Moving Toward Clinical Trials and Strengthening Leadership Team - Market Newsdesk","og_description":"BOSTON, March 16, 2021 (GLOBE NEWSWIRE) — TearClear continues to make progress on the development of its first-in-class platform of preservative-free topical medications. With a successful Pre-IND meeting with the US FDA achieved in Nov. 2020, the TearClear team is now advancing the preparation of clinical trial material required for its proprietary latanoprost pivotal study in anticipation of an IND submission later this year.\u00a0 Today, TearClear also announces the appointment of Stuart Raetzman to interim CEO. Stuart is a TearClear Board Member and long-term Industry veteran with a proven track record of building successful pharmaceutical businesses. Raetzman commented, \u201cTearClear thanks Robert Dempsey for his contributions and wishes him well. We are excited for the Company\u2019s next chapter as we scale … Continue reading \"TearClear Moving Toward Clinical Trials and Strengthening Leadership Team\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-moving-toward-clinical-trials-and-strengthening-leadership-team\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-16T11:31:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDg4MCM0MDY0ODUxIzIwODc3MjU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-moving-toward-clinical-trials-and-strengthening-leadership-team\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-moving-toward-clinical-trials-and-strengthening-leadership-team\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"TearClear Moving Toward Clinical Trials and Strengthening Leadership Team","datePublished":"2021-03-16T11:31:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-moving-toward-clinical-trials-and-strengthening-leadership-team\/"},"wordCount":327,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-moving-toward-clinical-trials-and-strengthening-leadership-team\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDg4MCM0MDY0ODUxIzIwODc3MjU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-moving-toward-clinical-trials-and-strengthening-leadership-team\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-moving-toward-clinical-trials-and-strengthening-leadership-team\/","name":"TearClear Moving Toward Clinical Trials and Strengthening Leadership Team - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-moving-toward-clinical-trials-and-strengthening-leadership-team\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-moving-toward-clinical-trials-and-strengthening-leadership-team\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDg4MCM0MDY0ODUxIzIwODc3MjU=","datePublished":"2021-03-16T11:31:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-moving-toward-clinical-trials-and-strengthening-leadership-team\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-moving-toward-clinical-trials-and-strengthening-leadership-team\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-moving-toward-clinical-trials-and-strengthening-leadership-team\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDg4MCM0MDY0ODUxIzIwODc3MjU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDg4MCM0MDY0ODUxIzIwODc3MjU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tearclear-moving-toward-clinical-trials-and-strengthening-leadership-team\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"TearClear Moving Toward Clinical Trials and Strengthening Leadership Team"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/458400","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=458400"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/458400\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=458400"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=458400"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=458400"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}